Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + paclitaxel + bevacizumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
The combination of carboplatin, paclitaxel, and bevacizumab is a chemotherapy regimen primarily used for the treatment of advanced non-small cell lung cancer (NSCLC) and certain gynecological cancers such as ovarian, fallopian tube, primary peritoneal cancer, and cervical cancer. Carboplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. Paclitaxel is a microtubule inhibitor that disrupts mitosis by stabilizing microtubules. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis required for tumor growth. The combination aims to maximize cytotoxic effects on tumor cells while also restricting their blood supply through antiangiogenic therapy[1][2][3][5].
- Brand names
- Avastin (bevacizumab)Taxol (paclitaxel)Paraplatin (carboplatin)
- Other names
- BCP regimen
02
Targets
Beyond the preview
Go deeper on carboplatin + paclitaxel + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + paclitaxel + bevacizumab.